Camelot Portfolios LLC Lowers Position in CVS Health Corporation (CVS)

Camelot Portfolios LLC lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 35.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,755 shares of the pharmacy operator’s stock after selling 2,040 shares during the quarter. Camelot Portfolios LLC’s holdings in CVS Health Corporation were worth $302,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mercer Capital Advisers Inc. purchased a new position in shares of CVS Health Corporation during the first quarter worth about $118,000. TB Alternative Assets Ltd. purchased a new position in shares of CVS Health Corporation during the second quarter worth about $121,000. Gemmer Asset Management LLC grew its holdings in shares of CVS Health Corporation by 15.3% during the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after buying an additional 200 shares during the last quarter. SRS Capital Advisors Inc. grew its holdings in shares of CVS Health Corporation by 48.2% during the first quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock worth $177,000 after buying an additional 734 shares during the last quarter. Finally, Grace & White Inc. NY purchased a new position in shares of CVS Health Corporation during the second quarter worth about $199,000. 81.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CVS Health Corporation (CVS) opened at 74.71 on Wednesday. The stock’s 50 day moving average is $79.46 and its 200-day moving average is $78.98. The firm has a market capitalization of $75.95 billion, a P/E ratio of 14.88 and a beta of 0.92. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $88.92.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.02. The business had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. On average, equities analysts forecast that CVS Health Corporation will post $5.88 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 3rd. Stockholders of record on Tuesday, October 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Monday, October 23rd. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.92%.

In other news, CFO David M. Denton sold 237,078 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry J. Merlo sold 241,150 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $83.07, for a total transaction of $20,032,330.50. Following the completion of the transaction, the insider now owns 299,255 shares of the company’s stock, valued at $24,859,112.85. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock valued at $58,318,431 over the last quarter. Insiders own 0.61% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Camelot Portfolios LLC Lowers Position in CVS Health Corporation (CVS)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/11/camelot-portfolios-llc-lowers-position-in-cvs-health-corporation-cvs.html.

CVS has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of CVS Health Corporation in a report on Sunday, September 10th. BidaskClub lowered CVS Health Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $95.00 price objective on shares of CVS Health Corporation in a report on Monday. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 3rd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $82.00 price objective on shares of CVS Health Corporation in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eight have given

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mercer Capital Advisers Inc. purchased a new position in shares of CVS Health Corporation during the first quarter worth about $118,000. TB Alternative Assets Ltd. purchased a new position in shares of CVS Health Corporation during the second quarter worth about $121,000. Gemmer Asset Management LLC grew its holdings in shares of CVS Health Corporation by 15.3% during the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after buying an additional 200 shares during the last quarter. SRS Capital Advisors Inc. grew its holdings in shares of CVS Health Corporation by 48.2% during the first quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock worth $177,000 after buying an additional 734 shares during the last quarter. Finally, Grace & White Inc. NY purchased a new position in shares of CVS Health Corporation during the second quarter worth about $199,000. 81.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CVS Health Corporation (CVS) opened at 74.71 on Wednesday. The stock’s 50 day moving average is $79.46 and its 200-day moving average is $78.98. The firm has a market capitalization of $75.95 billion, a P/E ratio of 14.88 and a beta of 0.92. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $88.92.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.02. The business had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. On average, equities analysts forecast that CVS Health Corporation will post $5.88 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 3rd. Stockholders of record on Tuesday, October 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Monday, October 23rd. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.92%.

In other news, CFO David M. Denton sold 237,078 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry J. Merlo sold 241,150 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $83.07, for a total transaction of $20,032,330.50. Following the completion of the transaction, the insider now owns 299,255 shares of the company’s stock, valued at $24,859,112.85. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock valued at $58,318,431 over the last quarter. Insiders own 0.61% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Camelot Portfolios LLC Lowers Position in CVS Health Corporation (CVS)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/11/camelot-portfolios-llc-lowers-position-in-cvs-health-corporation-cvs.html.

CVS has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of CVS Health Corporation in a report on Sunday, September 10th. BidaskClub lowered CVS Health Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $95.00 price objective on shares of CVS Health Corporation in a report on Monday. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 3rd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $82.00 price objective on shares of CVS Health Corporation in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the stock. CVS Health Corporation presently has an average rating of “Buy” and a consensus price target of $89.93.

CVS Health Corporation Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply